{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:41:24Z","timestamp":1790815284509,"version":"4.1.0"},"reference-count":149,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.ejmech.2023.115847","type":"journal-article","created":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T03:38:15Z","timestamp":1696045095000},"page":"115847","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Synthetic approaches and application of clinically approved small-molecule Anti-HIV drugs: An update"],"prefix":"10.1016","volume":"261","author":[{"given":"Lu","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Luan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piet","family":"Herdewijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115847_bib1","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1126\/science.8493571","article-title":"How does HIV cause AIDS?","volume":"260","author":"Weiss","year":"1993","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.ejmech.2023.115847_bib2","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1146\/annurev.med.60.041807.123549","article-title":"Emerging concepts in the immunopathogenesis of AIDS","volume":"60","author":"Douek","year":"2009","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ejmech.2023.115847_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162704","article-title":"Opportunistic infections in HIV-infected patients differ strongly in frequencies and spectra between patients with low CD4+ cell counts examined postmortem and compensated patients examined antemortem irrespective of the HAART Era","volume":"11","author":"Powell","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2023.115847_bib4","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/med.21760","article-title":"Druggability modification strategies of the diarylpyrimidine-type non-nucleoside reverse transcriptase inhibitors","volume":"41","author":"Ding","year":"2021","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2023.115847_bib5","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/sim.1342","article-title":"Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal","volume":"22","author":"Gilbert","year":"2003","journal-title":"Stat. Med."},{"key":"10.1016\/j.ejmech.2023.115847_bib6","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1099\/0022-1317-83-6-1253","article-title":"Human immunodeficiency virus type 2","volume":"83","author":"Reeves","year":"2002","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.ejmech.2023.115847_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114554","article-title":"HIV nucleoside reverse transcriptase inhibitors","volume":"240","author":"Amblard","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115847_bib8","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.apsb.2021.11.009","article-title":"Approved HIV reverse transcriptase inhibitors in the past decade","volume":"12","author":"Li","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2023.115847_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106783","article-title":"Development of novel HEPT analogs featuring significantly improved anti-resistance potency against HIV-1 through chemical space exploration of the tolerant region I","volume":"140","author":"Zhou","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2023.115847_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.apsb.2023.07.008","article-title":"Structure-based design of novel heterocycle-substituted ATDP analogs as non-nucleoside reverse transcriptase inhibitors with improved selectivity and solubility","author":"Zhao","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2023.115847_bib11","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1016\/j.apsb.2023.03.022","article-title":"Picomolar inhibitor of reverse transcriptase featuring significantly improved metabolic stability","volume":"13","author":"Sang","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2023.115847_bib12","article-title":"Structure-directed expansion of biphenyl-pyridone derivatives as potent non-nucleoside reverse transcriptase inhibitors with significantly improved potency and safety","author":"Zhao","year":"2023","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115847_bib13","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.apsb.2022.08.017","article-title":"Development of fluorine-substituted NH2-biphenyl-diarylpyrimidines as highly potent non-nucleoside reverse transcriptase inhibitors: boosting the safety and metabolic stability","volume":"13","author":"Jin","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2023.115847_bib14","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1021\/acs.jmedchem.1c01758","article-title":"Contemporary medicinal chemistry strategies for the discovery and development of novel HIV-1 non-nucleoside reverse transcriptase inhibitors","volume":"65","author":"Wang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115847_bib15","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1021\/acs.jmedchem.8b00843","article-title":"The journey of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) from lab to clinic","volume":"62","author":"Namasivayam","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115847_bib16","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1021\/acs.chemrev.0c00967","article-title":"Avoiding drug resistance in HIV reverse transcriptase","volume":"121","author":"Cilento","year":"2021","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2023.115847_bib17","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.apsb.2019.08.009","article-title":"Synthesis and biological evaluation of a series of 2-(((5-akly\/aryl-1H-pyrazol-3-yl)methyl)thio)-5-alkyl-6-(cyclohexylmethyl)-pyrimidin-4(3H)-ones as potential HIV-1 inhibitors","volume":"10","author":"Wu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2023.115847_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2022.101159","article-title":"Viral proteases as therapeutic targets","volume":"88","author":"Majerov\u00e1","year":"2022","journal-title":"Mol. Aspect. Med."},{"key":"10.1016\/j.ejmech.2023.115847_bib19","doi-asserted-by":"crossref","first-page":"11762","DOI":"10.1039\/D2CC04541A","article-title":"Beyond darunavir: recent development of next generation HIV-1 protease inhibitors to combat drug resistance","volume":"58","author":"Ghosh","year":"2022","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2023.115847_bib20","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1021\/acs.oprd.3c00063","article-title":"Synthetic approaches to a key pyridone-carboxylic acid precursor common to the HIV-1 integrase strand transfer inhibitors dolutegravir, bictegravir, and cabotegravir","volume":"27","author":"Mahajan","year":"2023","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.ejmech.2023.115847_bib21","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1128\/MMBR.00065-15","article-title":"HIV genome-wide protein associations: a review of 30 years of research","volume":"80","author":"Li","year":"2016","journal-title":"Microbiol. Mol. Biol. Rev. : MMBR (Microbiol. Mol. Biol. Rev.)"},{"key":"10.1016\/j.ejmech.2023.115847_bib22","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/13543776.2018.1438410","article-title":"Current insights into anti-HIV drug discovery and development: a review of recent patent literature (2014-2017)","volume":"28","author":"Zuo","year":"2018","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2023.115847_bib23","first-page":"815","article-title":"Multivalent agents: a novel concept and preliminary practice in Anti-HIV drug discovery","volume":"20","author":"Song","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115847_bib24","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1517\/17460441.2015.1083007","article-title":"Fragment-based approaches to anti-HIV drug discovery: state of the art and future opportunities","volume":"10","author":"Huang","year":"2015","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115847_bib25","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1039\/D0CS01084G","article-title":"Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses","volume":"50","author":"Ma","year":"2021","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2023.115847_bib26","first-page":"1","article-title":"Opportunities and challenges in new HIV therapeutic discovery: what is the next step?","author":"Xu","year":"2023","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115847_bib27","volume":"vol. 509","author":"Fischer","year":"2006"},{"key":"10.1016\/j.ejmech.2023.115847_bib28","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.gresc.2020.05.005","article-title":"Asymmetric catalysis in synthetic strategies for chiral benzothiazepines","volume":"1","author":"Wang","year":"2020","journal-title":"Green synthesis and catalysis"},{"key":"10.1016\/j.ejmech.2023.115847_bib29","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.gresc.2020.05.006","article-title":"Asymmetric catalytic hydrogenation of imines and enamines in natural product synthesis","volume":"1","author":"Tang","year":"2020","journal-title":"Green synthesis and catalysis"},{"key":"10.1016\/j.ejmech.2023.115847_bib30","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0040-4039(98)00131-2","article-title":"Practical synthesis of the anti-HIV drug, PMPA","volume":"39","author":"Schultze","year":"1998","journal-title":"Tetrahedron letter"},{"key":"10.1016\/j.ejmech.2023.115847_bib31","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1358\/dof.1998.023.12.479011","article-title":"(R)-PMPA and bis(POC)PMPA","volume":"23","author":"Sorbera","year":"1998","journal-title":"Drugs Future"},{"key":"10.1016\/j.ejmech.2023.115847_bib32","volume":"US5922695","author":"Arimilli","year":"1999"},{"key":"10.1016\/j.ejmech.2023.115847_bib33","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.gresc.2021.01.009","article-title":"Carbon dioxide cycle via electrocatalysis: electrochemical carboxylation of CO2 and decarboxylative functionalization of carboxylic acids","volume":"2","author":"Yang","year":"2021","journal-title":"Green synthesis and catalysis"},{"key":"10.1016\/j.ejmech.2023.115847_bib34","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1073\/pnas.85.13.4686","article-title":"Active human immunodeficiency virus protease is required for viral infectivity","volume":"85","author":"Kohl","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2023.115847_bib35","first-page":"95","article-title":"HIV protease inhibitors: a review of molecular selectivity and toxicity","volume":"7","author":"Lv","year":"2015","journal-title":"HIV\/AIDS"},{"key":"10.1016\/j.ejmech.2023.115847_bib36","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1021\/jm970873c","article-title":"New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development","volume":"41","author":"Bold","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115847_bib37","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1021\/jo00013a038","article-title":"Variable electronic properties of the CSNMe2 thioamide group","volume":"56","author":"Creary","year":"1991","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ejmech.2023.115847_bib38","volume":"US5849911","author":"Fassler","year":"1998"},{"key":"10.1016\/j.ejmech.2023.115847_bib39","series-title":"Bisulfate Salt of HIV Protease Inhibitor","author":"Singh","year":"2000"},{"key":"10.1016\/j.ejmech.2023.115847_bib40","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.gresc.2020.06.001","article-title":"Robust NHC-palladacycles-catalyzed Suzuki\u2212Miyaura cross-coupling of amides via C-N activation","volume":"1","author":"Deng","year":"2020","journal-title":"Green synthesis and catalysis"},{"key":"10.1016\/j.ejmech.2023.115847_bib41","series-title":"World Health Organization Model List of Essential Medicines: 21st List 2019","year":"2019"},{"key":"10.1016\/j.ejmech.2023.115847_bib42","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0166-0934(88)90134-6","article-title":"Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds","volume":"20","author":"Pauwels","year":"1988","journal-title":"J. Virol Methods"},{"key":"10.1016\/j.ejmech.2023.115847_bib43","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/hiv.12534","article-title":"Nucleoside reverse transcriptase inhibitor-reducing strategies in HIV treatment: assessing the evidence","volume":"19","author":"Orkin","year":"2018","journal-title":"HIV Med."},{"key":"10.1016\/j.ejmech.2023.115847_bib44","doi-asserted-by":"crossref","first-page":"9377","DOI":"10.1021\/ja00024a058","article-title":"In situ complexation directs the stereochemistry of N-glycosylation in the synthesis of thialanyl and dioxolanyl nucleoside analogs","volume":"113","author":"Choi","year":"1991","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2023.115847_bib45","doi-asserted-by":"crossref","first-page":"5563","DOI":"10.1021\/jo00047a004","article-title":"Enzyme-mediated enantioselective preparation of pure enantiomers of the antiviral agent 2',3'-dideoxy-5-fluoro-3'-thiacytidine (FTC) and related compounds","volume":"57","author":"Hoong","year":"1992","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ejmech.2023.115847_bib46","volume":"US5814639","author":"Liotta","year":"1998"},{"key":"10.1016\/j.ejmech.2023.115847_bib47","series-title":"Method for Preparing 1,3-oxiothionane and its Derivatives","author":"Liotta","year":"2002"},{"key":"10.1016\/j.ejmech.2023.115847_bib48","series-title":"Drugs and Lactation Database (LactMed\u00ae)","author":"Fosamprenavir","year":"2006"},{"key":"10.1016\/j.ejmech.2023.115847_bib49","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(06)69155-1","article-title":"The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial","volume":"368","author":"Eron","year":"2006","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ejmech.2023.115847_bib50","doi-asserted-by":"crossref","first-page":"5453","DOI":"10.1016\/00404-0399(50)1087X-","article-title":"Stereoselective synthesis of erythro \u03b1-amino epoxides","volume":"36","author":"Rotella","year":"1995","journal-title":"Tetrahedron letter"},{"key":"10.1016\/j.ejmech.2023.115847_bib51","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1016\/0040-4039(95)00533-I","article-title":"Large scale preparation of (2S, 3S)-N-Boc-3-amino-1, 2-epoxy-4-phenylbutane: a key building block for HIV-protease inhibitors","volume":"36","author":"Beaulieu","year":"1995","journal-title":"Tetrahedron letter"},{"key":"10.1016\/j.ejmech.2023.115847_bib52","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1358\/dof.2001.026.03.615590","volume":"26","author":"Sorbera","year":"2001","journal-title":"Fosamprenavir, Drugs of the future"},{"key":"10.1016\/j.ejmech.2023.115847_bib53","series-title":"Prodrugs of Aspartyl Protease Inhibitors","author":"Hale","year":"2002"},{"key":"10.1016\/j.ejmech.2023.115847_bib54","series-title":"Process for the Synthesis of HIV Protease Inhibitors","author":"Al-Farhan","year":"1998"},{"key":"10.1016\/j.ejmech.2023.115847_bib55","series-title":"Derivatives of (3s) Tetrahydro-3-Furanyl (1s,2r)-3-[[(4aminophenyl)sulfonyl](Isobutyl)amino]-1-Benzyl-2-(phosphonooxy)propylcarbamate","author":"Searle","year":"2001"},{"key":"10.1016\/j.ejmech.2023.115847_bib56","unstructured":"B. Ingelheim, New Aptivus\u00ae (Tipranavir) Oral Solution Approved for Treatment-Experienced Pediatric and Adolescent HIV Patients."},{"key":"10.1016\/j.ejmech.2023.115847_bib57","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1021\/acs.jmedchem.1c01912","article-title":"Discovery of potential neuroprotective agents against paclitaxel-induced peripheral neuropathy","volume":"65","author":"Chen","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115847_bib58","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1021\/jm9802158","article-title":"Tipranavir (PNU-140690): a Potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class","volume":"41","author":"Turner","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115847_bib59","first-page":"33","volume":"vol. 73","author":"Orkin","year":"2021"},{"key":"10.1016\/j.ejmech.2023.115847_bib60","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2147\/TCRM.S1709","article-title":"Combating HIV resistance - focus on darunavir","volume":"4","author":"Tremblay","year":"2008","journal-title":"Therapeut. Clin. Risk Manag."},{"key":"10.1016\/j.ejmech.2023.115847_bib61","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1128\/AAC.49.6.2314-2321.2005","article-title":"TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates","volume":"49","author":"De Meyer","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2023.115847_bib62","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1128\/AAC.00055-12","article-title":"Activity of human immunodeficiency virus type 1 protease inhibitors against the initial autocleavage in Gag-Pol polyprotein processing","volume":"56","author":"Davis","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2023.115847_bib63","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s12539-009-0043-8","article-title":"Structural basis for the resilience of Darunavir (TMC114) resistance major flap mutations of HIV-1 protease","volume":"1","author":"Purohit","year":"2009","journal-title":"Interdiscipl. Sci. Comput. Life Sci."},{"key":"10.1016\/j.ejmech.2023.115847_bib64","doi-asserted-by":"crossref","first-page":"7822","DOI":"10.1021\/jo049156y","article-title":"Stereoselective photochemical 1,3-dioxolane addition to 5-alkoxymethyl-2(5H)-furanone: synthesis of bis-tetrahydrofuranyl ligand for HIV protease inhibitor UIC-94017 (TMC-114)","volume":"69","author":"Ghosh","year":"2004","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ejmech.2023.115847_bib65","series-title":"Method of Preparing (3R, 3AS, 6AR)-3-hydroxyhexahydrofuro [2,3,-b] Furan and Related Compounds","author":"Ghosh","year":"2004"},{"key":"10.1016\/j.ejmech.2023.115847_bib66","series-title":"Drugs and Lactation Database (LactMed\u00ae)","author":"Maraviroc","year":"2006"},{"key":"10.1016\/j.ejmech.2023.115847_bib67","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1021\/ol503625z","article-title":"Highly efficient synthesis of HIV NNRTI doravirine","volume":"17","author":"Gauthier","year":"2015","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2023.115847_bib68","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/QAD.0b013e3283217f9f","article-title":"HIV pathogenesis: 25 years of progress and persistent challenges","volume":"23","author":"Levy","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.ejmech.2023.115847_bib69","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1517\/14656566.8.7.923","article-title":"Access denied? The status of co-receptor inhibition to counter HIV entry","volume":"8","author":"Biswas","year":"2007","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejmech.2023.115847_bib70","doi-asserted-by":"crossref","first-page":"15398","DOI":"10.1021\/ja075204v","article-title":"Asymmetric allylboration of acyl imines catalyzed by chiral diols","volume":"129","author":"Lou","year":"2007","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2023.115847_bib71","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.bmcl.2013.12.070","article-title":"Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses","volume":"24","author":"C\u00f4t\u00e9","year":"2014","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2023.115847_bib72","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1038\/s41467-021-21816-x","article-title":"Cryo-EM structures of HIV-1 trimer bound to CD4-mimetics BNM-III-170 and M48U1 adopt a CD4-bound open conformation","volume":"12","author":"Jette","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115847_bib73","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.3390\/v13071405","article-title":"Quaternary interaction of the HIV-1 envelope trimer with CD4 and neutralizing antibodies","volume":"13","author":"Liu","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2023.115847_bib74","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1021\/acs.jmedchem.5b00497","article-title":"Anti-HIV drug discovery and development: current innovations and future trends","volume":"59","author":"Zhan","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115847_bib75","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ijbiomac.2021.01.076","article-title":"Trends and strategies to combat viral infections: a review on FDA approved antiviral drugs","volume":"172","author":"Tompa","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejmech.2023.115847_bib76","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3390\/ph13060122","article-title":"Non-nucleoside reverse transcriptase inhibitors join forces with integrase inhibitors to combat HIV","volume":"13","author":"Himmel","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2023.115847_bib77","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1021\/op100257r","article-title":"Development of a second-generation, highly efficient manufacturing route for the HIV integrase inhibitor raltegravir potassium","volume":"15","author":"Humphrey","year":"2011","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.ejmech.2023.115847_bib78","series-title":"N-Substituted Hydroxypyrimidinone Carboxamide Inhibitors of HIV Integrase","author":"Crescenzi","year":"2007"},{"key":"10.1016\/j.ejmech.2023.115847_bib79","series-title":"Potassium Salt of an HIV Intergrase Inhibitor","author":"Belyk","year":"2006"},{"key":"10.1016\/j.ejmech.2023.115847_bib80","series-title":"Potassium Salt of an HIV Integrase Inhibitor","author":"Belyk","year":"2010"},{"key":"10.1016\/j.ejmech.2023.115847_bib81","series-title":"N-Substituted Hydroxypyrimidinone Carboxamide Inhibitors of HIV Integrase","author":"Crescenzi","year":"2003"},{"key":"10.1016\/j.ejmech.2023.115847_bib82","series-title":"Drugs and Lactation Database (LactMed\u00ae)","author":"Etravirine","year":"2006"},{"key":"10.1016\/j.ejmech.2023.115847_bib83","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1021\/acs.jmedchem.8b00843","article-title":"The journey of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) from lab to clinic","volume":"62","author":"Namasivayam","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115847_bib84","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1021\/op9003289","article-title":"An improved synthesis of etravirine","volume":"14","author":"Joshi","year":"2010","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.ejmech.2023.115847_bib85","series-title":"Process for Etravirine Intermediate and Polymorphs of Etravirine","author":"Reddy","year":"2013"},{"key":"10.1016\/j.ejmech.2023.115847_bib86","series-title":"A Process for Synthesis of Diarylpyrimidine Non-nucleoside Reverse Transcriptase Inhibitor","author":"Gurjar","year":"2010"},{"key":"10.1016\/j.ejmech.2023.115847_bib87","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.apsb.2019.11.010","article-title":"Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty years","volume":"10","author":"Zhuang","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2023.115847_bib88","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1021\/acs.jmedchem.9b01769","article-title":"Discovery and characterization of fluorine-substituted diarylpyrimidine derivatives as novel HIV-1 NNRTIs with highly improved resistance profiles and low activity for the hERG ion channel","volume":"63","author":"Kang","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115847_bib89","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1021\/acs.jmedchem.1c00268","article-title":"2,4,5-Trisubstituted pyrimidines as potent HIV-1 NNRTIs: rational design, synthesis, activity evaluation, and crystallographic studies","volume":"64","author":"Kang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115847_bib90","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.antiviral.2009.12.001","article-title":"TACE antagonists blocking ACE2 shedding caused by the spike protein of SARS-CoV are candidate antiviral compounds","volume":"85","author":"Haga","year":"2010","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2023.115847_bib91","doi-asserted-by":"crossref","first-page":"331","DOI":"10.5966\/sctm.2015-0168","article-title":"A disintegrin and metalloproteinase domain 17 regulates colorectal cancer stem cells and chemosensitivity via notch1 signaling","volume":"5","author":"Wang","year":"2016","journal-title":"Stem cells translational medicine"},{"key":"10.1016\/j.ejmech.2023.115847_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113868","article-title":"Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel","volume":"226","author":"Jin","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115847_bib93","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.1016\/j.bmc.2010.05.036","article-title":"Synthesis and anti-HIV activity of 2-naphthyl substituted DAPY analogues as non-nucleoside reverse transcriptase inhibitors","volume":"18","author":"Liang","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115847_bib94","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1128\/AAC.00986-09","article-title":"TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1","volume":"54","author":"Azijn","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2023.115847_bib95","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1021\/jm040838n","article-title":"Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1","volume":"48","author":"Guillemont","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115847_bib96","series-title":"HIV Inhibiting Pyrimidines Derivatives","author":"Guillemont","year":"2003"},{"key":"10.1016\/j.ejmech.2023.115847_bib97","series-title":"HIV Inhibiting Pyrimidines Derivatives","author":"Guillemont","year":"2004"},{"key":"10.1016\/j.ejmech.2023.115847_bib98","series-title":"Processes for the Preparation of 4","author":"Schils","year":"2004"},{"key":"10.1016\/j.ejmech.2023.115847_bib99","series-title":"Processes for the Preparation of 4","author":"Schils","year":"2006"},{"key":"10.1016\/j.ejmech.2023.115847_bib100","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ejmech.2006.11.014","article-title":"Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains","volume":"42","author":"Mordant","year":"2007","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115847_bib101","series-title":"Drugs and Lactation Database (LactMed\u00ae)","author":"Elvitegravir","year":"2006"},{"key":"10.1016\/j.ejmech.2023.115847_bib102","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1021\/jm900460z","article-title":"Quinolone carboxylic acids as a novel monoketo acid class of human immunodeficiency virus type 1 integrase inhibitors","volume":"52","author":"Sato","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115847_bib103","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.gresc.2021.10.002","article-title":"Palladium-catalyzed sulfonylative coupling of benzyl(allyl) carbonates with arylsulfonyl hydrazides","volume":"3","author":"Gong","year":"2022","journal-title":"Green synthesis and catalysis"},{"key":"10.1016\/j.ejmech.2023.115847_bib104","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1128\/AAC.01209-10","article-title":"In Vitro antiretroviral properties of S\/GSK1349572, a next-generation HIV integrase inhibitor","volume":"55","author":"Kobayashi","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2023.115847_bib105","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3109\/00498254.2014.942409","article-title":"The comparative disposition and metabolism of dolutegravir, a potent HIV-1 integrase inhibitor, in mice, rats, and monkeys","volume":"45","author":"Moss","year":"2015","journal-title":"Xenobiotica; the fate of foreign compounds in biological systems"},{"key":"10.1016\/j.ejmech.2023.115847_bib106","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1124\/mol.111.073189","article-title":"Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S\/GSK1349572)","volume":"80","author":"Hare","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115847_bib107","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1021\/jm400645w","article-title":"Carbamoyl pyridone HIV-1 integrase inhibitors 3. a diastereomeric approach to chiral nonracemic tricyclic ring systems and the discovery of dolutegravir (S\/GSK1349572) and (S\/GSK1265744)","volume":"56","author":"Johns","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115847_bib108","series-title":"Process for Preparing Compound Having HIV Integrase Inhibitory Activity","author":"Sumino","year":"2013"},{"key":"10.1016\/j.ejmech.2023.115847_bib109","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1021\/ml1000257","article-title":"Cobicistat (GS-9350): a potent and selective inhibitor of human CYP3A as a novel pharmacoenhancer","volume":"1","author":"Xu","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115847_bib110","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.tetlet.2008.11.071","article-title":"A novel and efficient synthesis of chiral C2-symmetric 1,4-diamines","volume":"50","author":"Xu","year":"2009","journal-title":"Tetrahedron letter"},{"key":"10.1016\/j.ejmech.2023.115847_bib111","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1080\/17460441.2017.1365056","article-title":"Ligand efficiency metrics in drug discovery: the pros and cons from a practical perspective","volume":"12","author":"Cavalluzzi","year":"2017","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115847_bib112","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1080\/00498254.2018.1451667","article-title":"Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans, Xenobiotica","volume":"49","author":"Sanchez","year":"2019","journal-title":"the fate of foreign compounds in biological systems"},{"key":"10.1016\/j.ejmech.2023.115847_bib113","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s13318-018-0497-3","article-title":"Clinical pharmacokinetics and drug interactions of doravirine","volume":"43","author":"Wilby","year":"2018","journal-title":"Eur. J. Drug Metabol. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2023.115847_bib114","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006882","article-title":"HIV-1 reverse transcription","volume":"2","author":"Hu","year":"2012","journal-title":"Cold spring harbor perspectives in medicine"},{"key":"10.1016\/j.ejmech.2023.115847_bib115","series-title":"Process for Making Reverse Transcriptase Inhibitors","author":"Itoh","year":"2014"},{"key":"10.1016\/j.ejmech.2023.115847_bib116","series-title":"Drugs and Lactation Database (LactMed\u00ae)","author":"Bictegravir","year":"2006"},{"key":"10.1016\/j.ejmech.2023.115847_bib117","series-title":"Preparation of Polycyclic-Carbamoylpyridone Compounds and Their Pharmaceutical Use","author":"Jin","year":"2014"},{"key":"10.1016\/j.ejmech.2023.115847_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112290","article-title":"hERG toxicity assessment: useful guidelines for drug design","volume":"195","author":"Garrido","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115847_bib119","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/med.21445","article-title":"Development of safe drugs: the hERG challenge","volume":"38","author":"Kalyaanamoorthy","year":"2018","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2023.115847_bib120","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1021\/acs.jmedchem.7b01337","article-title":"Inhibitors of HIV-1 attachment: the discovery and development of temsavir and its prodrug fostemsavir","volume":"61","author":"Meanwell","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115847_bib121","doi-asserted-by":"crossref","first-page":"a006924","DOI":"10.1101\/cshperspect.a006924","article-title":"HIV-1 assembly, budding, and maturation","volume":"2","author":"Sundquist","year":"2012","journal-title":"Cold spring harbor perspectives in medicine"},{"key":"10.1016\/j.ejmech.2023.115847_bib122","doi-asserted-by":"crossref","first-page":"8757","DOI":"10.1021\/jo5016008","article-title":"Synthesis of the 6-azaindole containing HIV-1 attachment inhibitor pro-drug, BMS-663068","volume":"79","author":"Chen","year":"2014","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ejmech.2023.115847_bib123","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1021\/acs.jmedchem.8b01729","volume":"62","author":"Huang","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115847_bib124","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1517\/13543780903055056","article-title":"Rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor","volume":"18","author":"Garvey","year":"2009","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2023.115847_bib125","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1039\/B711844A","article-title":"Understanding organofluorine chemistry. an introduction to the C-F bond","volume":"37","author":"O'Hagan","year":"2008","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2023.115847_bib126","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1021\/ol503580t","article-title":"An efficient and highly diastereoselective synthesis of GSK1265744, a potent HIV integrase inhibitor","volume":"17","author":"Wang","year":"2015","journal-title":"Organic letter"},{"key":"10.1016\/j.ejmech.2023.115847_bib127","series-title":"Processes for Preparing Dolutegravir and Cabotegravir and Analogues Thereof","author":"Maras","year":"2016"},{"key":"10.1016\/j.ejmech.2023.115847_bib128","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3390\/v13030417","article-title":"Interactions of HIV-1 capsid with host factors and their implications for developing novel therapeutics","volume":"13","author":"Zhuang","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2023.115847_bib129","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02057-20","article-title":"Absence of lenacapavir (GS-6207) phenotypic resistance in HIV gag cleavage site mutants and in isolates with resistance to existing drug classes","volume":"65","author":"Margot","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2023.115847_bib130","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1126\/science.abb4808","article-title":"Structural and mechanistic bases for a potent HIV-1 capsid inhibitor","volume":"370","author":"Bester","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2023.115847_bib131","series-title":"Methods and Intermediates for Preparation of Antiretroviral Pyridine Derivative Useful for Treatment of HIV-1 Infections","author":"Allan","year":"2019"},{"key":"10.1016\/j.ejmech.2023.115847_bib132","series-title":"Drugs and Lactation Database (LactMed\u00ae)","author":"Maraviroc","year":"2006"},{"key":"10.1016\/j.ejmech.2023.115847_bib133","series-title":"Drugs and Lactation Database (LactMed\u00ae)","author":"Ibalizumab","year":"2006"},{"key":"10.1016\/j.ejmech.2023.115847_bib134","series-title":"Emtricitabine and Tenofovir Disoproxil Fumarate","year":"2021"},{"key":"10.1016\/j.ejmech.2023.115847_bib136","series-title":"Drugs and Lactation Database (LactMed\u00ae)","author":"Darunavir","year":"2006"},{"key":"10.1016\/j.ejmech.2023.115847_bib137","series-title":"Drugs and Lactation Database (LactMed\u00ae)","author":"Raltegravir","year":"2006"},{"key":"10.1016\/j.ejmech.2023.115847_bib138","series-title":"Bevirimat","year":"2021"},{"key":"10.1016\/j.ejmech.2023.115847_bib139","series-title":"Fostemsavir Prescribing Information","year":"2020"},{"key":"10.1016\/j.ejmech.2023.115847_bib140","series-title":"Bamlanivimab for the Treatment of COVID-19","year":"2021"},{"key":"10.1016\/j.ejmech.2023.115847_bib141","unstructured":"D.D. Richman, Antiretroviral drug resistance, Antivir. Ther., 6(Suppl 3), 49-53."},{"key":"10.1016\/j.ejmech.2023.115847_bib142","first-page":"411","article-title":"Computational chemists in the new millennium","volume":"92","author":"Kitchen","year":"2003","journal-title":"J. Pharmaceut. Sci."},{"key":"10.1016\/j.ejmech.2023.115847_bib143","first-page":"573","article-title":"Tenofovir disoproxil fumarate","volume":"50","author":"Kearney","year":"2011","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2023.115847_bib145","first-page":"1390","article-title":"HIV treatment costs and uninsured people living with HIV in the United States","volume":"29","author":"Becker","year":"2017","journal-title":"AIDS Care"},{"key":"10.1016\/j.ejmech.2023.115847_bib146","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/COH.0b013e32833a0b69","article-title":"Pharmacology of antiretroviral drugs in the female genital tract for HIV prevention","volume":"5","author":"Colbers","year":"2010","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.ejmech.2023.115847_bib147","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1097\/QAD.0b013e328353f3f1","article-title":"HIV reservoirs: pathogenesis and obstacles to viral eradication and cure","volume":"26","author":"Chun","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.ejmech.2023.115847_bib148","first-page":"381","article-title":"CRISPR-Cas9: a tool for cancer research and therapeutics","volume":"14","author":"Khalili","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2023.115847_bib149","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11904-017-0353-0","article-title":"Long-acting antiretrovirals: where are we now?","volume":"14","author":"Nyaku","year":"2017","journal-title":"Current HIV\/AIDS reports"},{"key":"10.1016\/j.ejmech.2023.115847_bib150","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa1506110","article-title":"Use of a vaginal ring containing dapivirine for HIV-1 prevention in women","volume":"375","author":"Baeten","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2023.115847_bib151","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"363","author":"Grant","year":"2010","journal-title":"N. Engl. J. Med."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423008140?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423008140?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:01:30Z","timestamp":1759330890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423008140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":149,"alternative-id":["S0223523423008140"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115847","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthetic approaches and application of clinically approved small-molecule Anti-HIV drugs: An update","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115847","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115847"}}